Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

    Funding support available to study and prove effectiveness of potential neurotherapeutic agents for neurological disorders towards further development.

    Browse similar grants
    Neuroscience Research Grants 2026
    OverviewSimilar Grants
    OverviewSimilar Grants

    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

    Grant supports developing assays to find new therapies for brain and muscle diseases within IGNITE program; doesn't fund clinical trials.

    HHS-NIH11Due Feb 18, 2027$750,000

    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

    This grant supports creating and validating animal models and tissue systems mimicking neurological disorders to advance neurotherapeutic discovery.

    HHS-NIH11Due Feb 18, 2027$750,000

    NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)

    Supports investigator-initiated clinical trials for neurological disorders, from early exploratory studies to Phase 3 confirmatory and comparative effectiveness trials.

    HHS-NIH11Due Feb 10, 2027

    Translational Neural Devices (R61/R33 - Clinical Trial Optional)

    Encourages translational activities and small clinical studies for neural devices to address disorders affecting the nervous system; includes prototype development, safety testing, and clinical validation.

    HHS-NIH11Due Jan 28, 2027

    Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)

    NIH supports discovery of in vivo chemical probes for novel brain targets, with applicants expected to have validated starting compounds and bioassays; clinical trials are not allowed.

    HHS-NIH11Due Feb 5, 2027